title: Long-term treatment with bromocriptine of a plurihormonal pituitary adenoma secreting thyrotropin, growth hormone and prolactin.
abstract: A 48-year-old female presented with acromegaly, amenorrhea and hyperthyroidism associated with high serum free T4 levels and measurable TSH concentrations. The administration of GHRH induced significant increases in GH, PRL and TSH. Conversely, intravenous infusion of dopamine or oral administration of bromocriptine effectively inhibited GH, PRL and TSH secretion. Serum alpha-subunit levels were neither affected by GHRH, dopamine nor bromocriptine. Transsphenoidal surgery was performed and immunostaining of the tissue showed that the adenoma cells were positive for GH, PRL or TSH. The patient was treated with bromocriptine at a daily oral dose of 10 mg after surgery. Serum TSH were initially suppressed but returned within reference intervals with persistent normalized free T4 levels. Serum PRL became undetectable and GH levels were stable around 6 ng/ml except the periods of poor drug compliance, when serum TSH, GH and PRL levels rose considerably. The patient was followed-up for 10 years without any change in the residual adenoma tissues as detected by magnetic resonance imaging. These findings suggest that long-term bromocriptine therapy is effective in treating the hypersecretory state of a plurihormonal adenoma secreting TSH, GH and PRL.
authors.affiliation: Department of Laboratory Medicine, Kyoto University Graduate School of Medicine, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Shimatsu
authors.forename: H
authors.initials: H
authors.lastname: Murabe
authors.forename: Y
authors.initials: Y
authors.lastname: Nakamura
authors.forename: H
authors.initials: H
authors.lastname: Mizuta
authors.forename: C
authors.initials: C
authors.lastname: Ihara
authors.forename: K
authors.initials: K
authors.lastname: Nakao
mesh_terms: D000172:Acromegaly / Q000209:etiology; D000236:Adenoma / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism*; D000568:Amenorrhea / Q000209:etiology; D001971:Bromocriptine / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D013007:Growth Hormone-Releasing Hormone; D006727:Hormone Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D019382:Human Growth Hormone / Q000378:metabolism*; D006801:Humans; D006980:Hyperthyroidism / Q000209:etiology; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism*; D011388:Prolactin / Q000378:metabolism*; D012016:Reference Values; D013972:Thyrotropin / Q000378:metabolism*; D013973:Thyrotropin-Releasing Hormone; D013974:Thyroxine / Q000097:blood
chemical_list: D006727:Hormone Antagonists; D019382:Human Growth Hormone; D001971:Bromocriptine; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin; D013972:Thyrotropin; D013007:Growth Hormone-Releasing Hormone; D013974:Thyroxine